Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ADMENYSEAMERICAN:ASTCVE:STA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMEAptus Drawdown Managed Equity ETF$46.68+0.8%$45.26$39.85▼$48.57$236.38M0.7925,171 shs3,726 shsASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsSTASanatana ResourcesC$0.74C$0.42C$0.08▼C$0.94C$75.36M1.32108,859 shs73,350 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMEAptus Drawdown Managed Equity ETF-0.21%-0.28%+1.58%+4.50%+6.48%ASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%STASanatana Resources0.00%-10.84%+82.72%+604.76%+722.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMEAptus Drawdown Managed Equity ETFN/AN/AN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMEAptus Drawdown Managed Equity ETF 2.70Moderate Buy$46.68N/AASTAsterias Biotherapeutics 0.00N/AN/AN/ASTASanatana Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMEAptus Drawdown Managed Equity ETFN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AC$0.16 per share4.71C$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMEAptus Drawdown Managed Equity ETFN/AN/A26.13∞N/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ASTASanatana Resources-C$2.27M-C$0.01N/A∞N/AN/A-58.40%-54.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMEAptus Drawdown Managed Equity ETF$0.210.45%N/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMEAptus Drawdown Managed Equity ETFN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/ASTASanatana Resources3.475.532.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMEAptus Drawdown Managed Equity ETFN/AASTAsterias BiotherapeuticsN/ASTASanatana ResourcesN/AInsider OwnershipCompanyInsider OwnershipADMEAptus Drawdown Managed Equity ETFN/AASTAsterias BiotherapeuticsN/ASTASanatana Resources10.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMEAptus Drawdown Managed Equity ETFN/A4.92 millionN/ANot OptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableSTASanatana Resources3101.84 millionN/ANot OptionableADME, STA, AST, and UKOG HeadlinesRecent News About These CompaniesOff-market insider buying at Sanatana Resources (STA)June 14, 2025 | theglobeandmail.comSanatana Resources (CVE:STA) Trading Up 16.9% - Still a Buy?June 11, 2025 | marketbeat.comSanatana Resources (CVE:STA) Shares Up 16.9% - Time to Buy?June 11, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 17.9% Higher - Time to Buy?June 6, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading Up 16.4% - Time to Buy?June 6, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading Up 19.4% - Time to Buy?June 6, 2025 | marketbeat.comSanatana Resources (CVE:STA) Reaches New 1-Year High - Should You Buy?June 5, 2025 | marketbeat.comSanatana Announces Closing of the Acquisition of the Gold Strike Two Project and the Concurrent Oversubscribed Private PlacementJune 4, 2025 | finance.yahoo.comSanatana Resources Completes Acquisition and Raises $1.38M in Private PlacementJune 4, 2025 | tipranks.comSanatana Resources (CVE:STA) Shares Up 46.7% - Here's What HappenedMay 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Stock Price Up 46.7% - Still a Buy?May 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Shares Up 46.7% - Should You Buy?May 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Shares Up 46.7% - Still a Buy?May 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Here's WhyMay 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Shares Up 29.1% - Here's WhyMay 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 18.2% Higher - Here's WhyMay 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 21.8% Higher - Here's WhyMay 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Shares Up 20% - Should You Buy?May 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Still a Buy?May 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Time to Buy?May 31, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Here's What HappenedMay 31, 2025 | marketbeat.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle Recovery3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst Optimism3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherADME, STA, AST, and UKOG Company DescriptionsAptus Drawdown Managed Equity ETF BATS:ADME$46.68 +0.35 (+0.76%) Closing price 06/20/2025 03:55 PM EasternExtended Trading$46.65 -0.03 (-0.06%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Aptus Drawdown Managed Equity ETF (ADME) is an exchange-traded fund that mostly invests in large cap equity. The fund is actively managed to select large-cap US stocks that exhibit positive fundamental and momentum characteristics combined with a downside hedge. ADME was launched on Jun 8, 2016 and is managed by Aptus.Asterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Sanatana Resources CVE:STAC$0.74 0.00 (0.00%) As of 06/20/2025 03:20 PM EasternSanatana Resources Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties. It explores for copper and gold. The company entered in an option agreement to acquire 80% interest in the Oweegee Dome project covering an area of approximately 31,077 hectares located in in Golden Triangle in British Columbia; and 100% interest in the Empress Property, as well as asset purchase agreement to acquire the Santoy Property comprising 32 cell mining claims covering an area of approximately 551 hectares located in in Ontario. It also holds interests in the Fortune Project consisting of 100% interest in the Enid property, which comprises 41 mineral claims in the Timmins, Ontario region. The company was formerly known as Sanatana Diamonds Inc. and changed its name to Sanatana Resources Inc. in April 2011. Sanatana Resources Inc. was incorporated in 2004 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
